Management of totally implantable vascular access devices in patients with cystic fibrosis

Minerva Pediatrica

Volumn 61, Issue 5, 2009, Pages 549-555

  Dal Molin, A ^a   Gatta, C ^a   Festini, F ^b  

^a OSPEDALE DEGLI INFERMI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Catheterization, complications; Cystic fibrosis; Infection; Thrombosis

Indexed keywords

ALCOHOL; ALTEPLASE; BICARBONATE; CHLORHEXIDINE; HEPARIN; HYDROCHLORIC ACID; SODIUM HYDROXIDE; UROKINASE;

AIR EMBOLISM; ANTIBIOTIC THERAPY; ANTISEPSIS; ARTERY INJURY; CATHETER INFECTION; CATHETER OCCLUSION; CATHETER THROMBOSIS; CHILD; CYSTIC FIBROSIS; DYSPNEA; FATIGUE; FORCED EXPIRATORY VOLUME; HEMATOMA; HOME CARE; HUMAN; IMPLANT; PNEUMOTHORAX; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; REVIEW; VASCULAR ACCESS; VEIN THROMBOSIS; WOUND DRESSING;

ANTI-BACTERIAL AGENTS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CHLORHEXIDINE; CYSTIC FIBROSIS; DISINFECTANTS; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, INTRAVENOUS; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF CONCEPT; TIME FACTORS; VENOUS THROMBOSIS;

EID: 75149192169     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Hatchard L, O'Leary S. Preoperative awareness for children with implantable ports. Journal of Child Health Care 1999;2:20-3.
2. Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E. Totally implanted venous and arterial access system to replace external catheter in cancer treatment. Surgery 1982;92:706-12.
3. Munck A, Malbezin S, Bloch J, Gerardin M, Lebourgeois M, Derelle J et al. Follow-up of 452 totally implantable vascular devices in CF patients. Eur Respir J 2004;23:430-4.
4. Vescia S, Baumgärtner AK, Jacobs VR, Kiechle-Bahat M, Rody A, Loibl S et al. Management of venous port systerns in oncology: a review of current evidence. Annals of Oncology 2008;19:9-15.
5. Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota DM. Complication and failure of subclavian-vein catheterization. N Engl J Med 1994;331:1735-8.
6. Rodgers HC, Liddle K, Nixon SJ, Innes JA, Greening AP. Totally implantable venous access devices in CF: complications and patients' opinions. Eur Respir J 1998;12:217-20.
7. Santilli J. Fibrin sheaths and central venous catheter occlusions: diagnosis and management. Tech Vasc Interv RAdiol 2002;5:89-94.
8. Bouza E, Burillo A, Munoz P. Catheter-related infections: diagnosis and intravascular treatment. Clin Microbiol Infect 2002;8:265-74.
9. Kariyawasam HH, Pepper JR, Hodson ME, Geddes DM. Experience of totally implantable venous access devices (TIVADs) in adults with cystic fibrosis over a 13-year period. Respir Med 2000;12:1161-5.
10. Gaber KA, Shenton L, Oades P, Colville A, Sheldon CD. Fungal septicaemia in patients with cystic fibrosis associated with totally implantable venous access device system. J Cyst Fibros 2007;6:317-9.
11. Barker M, Thoenes D, Döhmen H, Friedrichs F, Pfannenstiel C, Heimann G. Prevalence of thrombophilia and catheter-related thrombosis in cystic fibrosis. Pediatr Pulmonol 2005;2:156-61.
12. Balfour-Lynn IM, Malbon K, Burman JF, Davidson SJ. Thrombophilia in children with cystic fibrosis. Pediatr Pulmonol 2005;4:306-10.
13. RNAO Guidelines: Registered Nurses' Association of Ontario. Care and Maintenance to Reduce Vascular Access Complications; 2005; Toronto, Canada, [cited 2009 September 9]. Available at www.rnao.org
14. Mezey M, Schoder J. Patients older than 65 are hospitals' "core business". J Infus Nurs 2003;26:125-6.
15. Long MC, Ovaska M. Comparative study of nursing protocols for venous access ports. Cancer Nurs 1992;1:18-21.
16. Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular - catheter related infections. MMWR Morb Mortal Wkly Rep 2002;51:1-29.
17. NICE Guidelines National Health System - National Institute for Clinical Excellence Infection Control. Prevention of healthcare associated infection in primary and community care. Care of patients with central venous catheter 2003; London. Available at www.evanetwork.info
18. Richards DM, Hill J, Scott NA, Bancewicz J, Irving M. Open technique has lower evidence of Complications. Br Med J 1995;311:1090.
19. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999;20: 250-78.
20. Lewis CA, Allen TE, Burke DR, Cardella JF, Citron SJ, Cole PE et al. Quality improvement guidelines for central venous access. J Vase Interv Radiol 1003;14:S231-S5.
21. Mazzufero F. Gestione degli accessi venosi centrali, GAVeCeLT 2005. [Accesso 2007 novembre 20; citato 2009 settembre 9]. Disponibile su: http://www.gave-celt.info/modules/PDdownloads/singlefile.php?cid=8&lid=39
22. Tropp J, Bagnall-Reeb H, Gorski L, Hadaway L, Hunter M, Roth D, Saxton J. Infusion nursing standards of practice. J Infus Nurs 2006;29:15.
23. Milani A, Vernizzi S, Passoni C, Sociale O, Macciola F, Grimaldi C et al. Huber needle in situ in patients under continuous infusion chemotherapy: results of a phase II study. Prof Inferm 2000;53:71-4.
24. Karamanoglu A, Yumuk PF, Gumus M, Ekenel M, Aliustaoglu M, Selimen D et al. Port needles: do they need to be removed as frequently in infusional chemotherapy? J Infus Nurs 2003;26:239-42.
25. Pratt RJ, Pellowe CM, Wilson JA, Loveday HP, Harper PJ, Jones SR et al. epic2: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect 2007; 65(Suppl 1):S1-64.
26. Mimoz O, Villeminey S, Ragot S, Dahyot-Fizelier C, Laksiri L, Petitpas F et al. Clorexidina - Based Antiseptic Solution vs. Alcohol - Based Povidone - Iodine for Central Venous Catheter Care. Arch Intern Med 2007;167:2066-72.
27. Dougherty L. Central venous access devices. Care and Management (Blackwell Publishing, Oxford) 2006:99.
28. Gillies D, Carr D, Frost J, O'Riordan E, Gunning R, O'Brien I. Gauze and tape and transparent polyurethane dressings for central venous catheters. The Cochrane Collaboration 2003.
29. O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2002;30:476-89.
30. RNAO Guidelines: Registered Nurses Association of Ontario. Assessment and Device Selection for Vascular Access. Nursing Best Practice Guideline; 2004. [cited 2009 September 9]. Available at: www.evanetwork.info
31. Kuo YS, Schwartz B, Santiago J, Anderson P.S. Fields A.L. Gary L et al. How often should a port-A-cath be flushed? Cancer Invest 2005;25:582-5.
32. Intravenous Nurses Society. Infusion nursing: standard of practice. J Intraven Nurs 2000:23:S1-S88.
33. RCN Standards - Royal College of Nurses: Standards for infusion therapy, 2005. [cited 2009 September 91. Available at: www.gavecelt.info
34. Kelly C, Dumenko L, McGregor E, McHutchion E, A change in flushing protocols of central venous catheters; Oncol Nurs Fourm 1992;19:599-605.
35. Shepherd A, Williams N. Care of long-term central venous catheters. Br J Hosp Med 1994;51:598-602.
36. Wickham RS, Advances in venous access devices and nursing management strategies. Nurs Clin North Am 1990;25:345-64.
37. Simon A, Bode U, Lieber K, Beutel K, Fleischhack G, Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients; Am J Infect Control 2008;36:54-8.
38. Haire WD, Deitcher SR, Mullane KM, Jaff MR, Firszt CM, Schulz GA et al. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. Thromb Haemost 2004;92:575-82.
39. Svoboda P, Barton RP, Barbarash OL, Butylin AA, Jacobs BR, Lata J et al. Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial. Crit Care Med 2004;32:1990-6.
40. Deitcher SR, Fesen MR, Kiproff PM, Hill PA, Li X, McCluskey ER et al. Cardiovascular Thrombolytic to Open Occluded Lines-2 Investigators, Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial; J Clin Oncol 2002;20:317-24.
41. Timoney JP, Malkin MG, Leone DM, Groeger JS, Heaney ML, Keefe DL et al. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices. J Clin Oncol 2002;20:1918-22.
42. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER; COOL Investigators, Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial - the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vase Interv Radiol 2001;12:951-5.
43. Blaney M, Shen V, Kerner JA, Jacobs BR, Gray S, Armfield J et al. CAPS Investigators, Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study). Vase Interv Radiol 2006;17:1745-51.
44. Semba CP, Deitcher SR, Li X, Resnansky L, Tu T, McCluskey ER. Cardiovascular thrombolytic to Open Occluded Lines Investigators, Treatment of occluded central venous catheters with alteplase: results in 1 064 patients. J Vase Interv Radiol 2002;13:1199-205.
45. Deerojanawong J, Sawyer SM, Fink AM, Stokes KB, Robertson CF. Totally implantable venous access devices in children with CF: incidence and type of complications. Thorax 1998;53;285-9.
46. Asensio O, Bosque M, Marco T, de Grace J, Serra C. Home intravenous antibiotics for CF. The Cochrane Collaboration 2004.
47. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. European Respir J 1997;10:896-900.
48. Ostrow LS. Air embolism and central venous lines. Am J Nurs 1981;81:11:2036-8.
49. Lambert MJ. Air embolism in central venous catheterization: diagnosis, treatment, and prevention. South Med J 1982;75:1189-91.
50. Laskey AL, Dyer C, Tobias JD. Venous air embolism during home infusion therapy. Pediatrics 2002;109:E15.
51. Burdon J, Conway SP, Murchan P, Lansdown M, Kester RC. Five years' experience of PAS Port intravenous access system in adult CF. Eur Resp J 1998;12:212-6.
52. Littlewood J, Balfour-Lynn I, Barnes R, Bilton D, Dinwiddie R, Doull I et al. Standards for the clinical care of children and adults with cystic fibrosis. UK CF Trust 2001.
53. Kerem E, Conway S, Elborn S, Heijerman H. Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005;4:7-26.
54. Ballarin S, Milella I, Bergamin L, Ardia R, Codamo T, Colosi A et al. Uso del catetere venoso centrale nei pazienti con fibrosi cistica: un'indagine nazionale. Minerva Med 2006;97(Suppl. 1 al N. 6):139.
55. Ballarin S, Milella I, Bergamin L, Festini F. Use of central venous catheters in people with cystic fibrosis in Italy. J Cyst Fibros 2007;6(Suppl 1):81.
56. A-Rahman A, Spencer D. Totally implantable vascular access devices for cystic fibrosis. The Cochrane Collaboration 2003.